So we are worried about mid-cap pharma which we used to be very positive about it. So I think clearly from long-term perspective, Infosys is the key theme which we are looking at and I think Infosys has been outperformer right from September 2014. So I think market is also expanding. It is not necessary the same Sun Pharma will perform, something else will perform, maybe it is not necessary TCS will perform, maybe Infosys is performing. For a few years it is history, not for an unlimited time frame but for few years definitely history.

Source: Economic Times June 11, 2016 07:58 UTC